Stephen J. Freedland, MD

January 18, 2023

Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.

January 18, 2023

Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.

January 18, 2023

Stephen J. Freedland, MD, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case and outlines which factors, including clinical data, inform his treatment decision-making.

January 18, 2023

Dr Stephen J. Freedland reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.